129 related articles for article (PubMed ID: 2549606)
1. Metabolism of gyrase inhibitors.
Sörgel F
Rev Infect Dis; 1989; 11 Suppl 5():S1119-29. PubMed ID: 2549606
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of gyrase inhibitors, Part 2: Renal and hepatic elimination pathways and drug interactions.
Sörgel F; Kinzig M
Am J Med; 1993 Mar; 94(3A):56S-69S. PubMed ID: 8383921
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic disposition of quinolones in human body fluids and tissues.
Sörgel F; Jaehde U; Naber K; Stephan U
Clin Pharmacokinet; 1989; 16 Suppl 1():5-24. PubMed ID: 2653696
[TBL] [Abstract][Full Text] [Related]
4. Bacterial topoisomerases, anti-topoisomerases, and anti-topoisomerase resistance.
Hooper DC
Clin Infect Dis; 1998 Aug; 27 Suppl 1():S54-63. PubMed ID: 9710672
[TBL] [Abstract][Full Text] [Related]
5. [Biotransformation of selected gyrase inhibitors].
Borner K; Lode H
Infection; 1986; 14 Suppl 1():S54-9. PubMed ID: 3007367
[TBL] [Abstract][Full Text] [Related]
6. Quinolone mode of action.
Hooper DC
Drugs; 1995; 49 Suppl 2():10-5. PubMed ID: 8549276
[TBL] [Abstract][Full Text] [Related]
7. 4-quinolones and the physiology of DNA gyrase.
Drlica K; Kreiswirth B
Adv Pharmacol; 1994; 29A():263-83. PubMed ID: 7826862
[No Abstract] [Full Text] [Related]
8. The inhibition of supercoiling activity of DNA gyrase from Micrococcus luteus caused by rufloxacin (MF 934) and MF 961.
Fabbri S; Broggini M; Pagella P; D'Incalci M
J Antimicrob Chemother; 1991 May; 27(5):687-9. PubMed ID: 1653205
[No Abstract] [Full Text] [Related]
9. Mode of action of the new quinolones: new data.
Hooper DC; Wolfson JS
Eur J Clin Microbiol Infect Dis; 1991 Apr; 10(4):223-31. PubMed ID: 1650698
[TBL] [Abstract][Full Text] [Related]
10. Molecular mechanisms of DNA gyrase inhibition by quinolone antibacterials.
Shen LL
Adv Pharmacol; 1994; 29A():285-304. PubMed ID: 7826863
[No Abstract] [Full Text] [Related]
11. Pharmacokinetics of gyrase inhibitors, Part 1: Basic chemistry and gastrointestinal disposition.
Sörgel F; Kinzig M
Am J Med; 1993 Mar; 94(3A):44S-55S. PubMed ID: 8383920
[TBL] [Abstract][Full Text] [Related]
12. Inhibitory activity of quinolones against DNA gyrase of Mycobacterium tuberculosis.
Onodera Y; Tanaka M; Sato K
J Antimicrob Chemother; 2001 Apr; 47(4):447-50. PubMed ID: 11266418
[TBL] [Abstract][Full Text] [Related]
13. The interaction of drugs with DNA gyrase: a model for the molecular basis of quinolone action.
Heddle JG; Barnard FM; Wentzell LM; Maxwell A
Nucleosides Nucleotides Nucleic Acids; 2000 Aug; 19(8):1249-64. PubMed ID: 11097055
[TBL] [Abstract][Full Text] [Related]
14. DNA gyrase as a drug target.
Maxwell A
Biochem Soc Trans; 1999 Feb; 27(2):48-53. PubMed ID: 10093705
[No Abstract] [Full Text] [Related]
15. Role of the extended alpha4 domain of Staphylococcus aureus gyrase A protein in determining low sensitivity to quinolones.
Strahilevitz J; Robicsek A; Hooper DC
Antimicrob Agents Chemother; 2006 Feb; 50(2):600-6. PubMed ID: 16436716
[TBL] [Abstract][Full Text] [Related]
16. [Inhibition of gyrase by 4-quinolones: effect on the structure of DNA].
Weisser J; Wiedemann B
Infection; 1986; 14 Suppl 3():S183-5. PubMed ID: 3019897
[TBL] [Abstract][Full Text] [Related]
17. [Gyrase inhibitors, a new class of therapeutic drugs].
Petzinger E
Tierarztl Prax; 1991 Feb; 19(1):14-20. PubMed ID: 2048102
[TBL] [Abstract][Full Text] [Related]
18. [Quinolones. Gyrase inhibitors].
Höffler D
Internist (Berl); 1994 May; 35(5):484-9. PubMed ID: 8021119
[No Abstract] [Full Text] [Related]
19. [Should the use of gyrase inhibitors be limited to hospitals?].
Shah PM
Immun Infekt; 1990 Jun; 18(3):69-70. PubMed ID: 2165996
[No Abstract] [Full Text] [Related]
20. Clerocidin, a terpenoid antibiotic, inhibits bacterial DNA gyrase.
McCullough JE; Muller MT; Howells AJ; Maxwell A; O'Sullivan J; Summerill RS; Parker WL; Wells JS; Bonner DP; Fernandes PB
J Antibiot (Tokyo); 1993 Mar; 46(3):526-30. PubMed ID: 8386713
[No Abstract] [Full Text] [Related]
[Next] [New Search]
